Browse the evidence

SGLT2 inhibitors (specifically empagliflozin and canagliflozin) provide significant cardiovascular benefits, particularly reducing cardiovascular death and heart failure hospitalizations, primarily through hemodynamic mechanisms like intravascular volume reduction, with efficacy potentially modified by the duration of diabetes.

If you have Type 2 Diabetes and existing heart issues, ask your doctor about SGLT2 inhibitors like empagliflozin. They have been proven to significantly reduce the risk of dying from heart causes and hospitalizations for heart failure, likely by reducing fluid volume in the body. This benefit is most pronounced in patients with established cardiovascular disease.

Intensive glycemic control reduces cardiovascular mortality only in patients with early-stage diabetes (duration <10-15 years), whereas it may increase mortality in patients with long-standing diabetes.

If you have had Type 2 Diabetes for many years (over 10), aiming for very low blood sugar levels might actually increase your risk of death due to side effects like severe hypoglycemia. Focus on stable control rather than aggressive lowering. If you have recently been diagnosed, aggressive control can provide long-term 'legacy' protection for your heart.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, intraglomerular hypertension, and direct adipose tissue endocrine effects, independent of diabetes and hypertension.

High body weight, particularly visceral fat, directly stresses the kidneys through increased pressure and inflammatory signals, leading to chronic kidney disease even without diabetes. Managing weight through lifestyle changes is a primary strategy to prevent kidney damage.

High consumption of artificially-sweetened beverages (ASBs) is not significantly associated with increased cardiovascular disease risk in physically active individuals.

If you are physically active, drinking two or more artificially-sweetened beverages a day does not appear to increase your cardiovascular disease risk in this study. However, this does not mean they are 'healthy,' and they should not be relied upon as a primary health strategy.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.

GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.

In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.

Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.

GLP-1 receptor agonists significantly delay gastric emptying and increase residual gastric content, but do not significantly increase the absolute risk of pulmonary aspiration in standard endoscopic procedures.

If you take GLP-1s (like Ozempic or Wegovy) for an endoscopy, expect your stomach to empty slower, but know the risk of lung infection is very low. You likely do not need to stop your medication unless you have specific symptoms or high-risk procedures. Follow extended clear-liquid fasting instructions and use gastric ultrasound if available to ensure safety.

GLP-1 receptor agonists impair colonic preparation and delay capsule transit, increasing the likelihood of inadequate bowel cleansing and the need for repeat colonoscopies.

If you take GLP-1s for a colonoscopy, your bowel prep might be less effective than usual. You may need a more intensive prep regimen (like extended clear liquids or additional laxatives) to ensure the doctor can see clearly. This is common and manageable.

Pharmacological inhibition of angiotensin-converting enzyme (ACE) using enalapril (20 mg/day) during 8 weeks of high-intensity training significantly attenuates exercise-induced increases in lean body mass in healthy adults, while peripheral muscle adaptations and aerobic performance remain unaffected.

If you are taking ACE inhibitors (like enalapril or lisinopril) for blood pressure, be aware that these medications may blunt your muscle growth potential compared to not taking them. This does not mean you cannot build strength or endurance, but your muscle mass gains may be reduced. Focus on consistent training and nutrition, and consult your doctor before making any medication changes.

The ACE I/D genotype is a poor predictor of actual ACE enzyme activity and downstream exercise adaptations because it is in linkage disequilibrium with functional variants and does not consistently correlate with circulating Angiotensin II levels.

Do not rely solely on genetic testing (like ACE I/D) to predict your athletic potential or training response. These tests are often poor predictors of actual performance or muscle growth. Instead, focus on consistent training, proper nutrition, and recovery. If you are curious about your biology, direct measurement of enzyme activity (phenotyping) is more informative than genetic markers alone.

Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.

Stop relying on willpower and calorie counting alone to cure obesity. Your body is biologically fighting to keep its weight at a higher 'set point' through hunger hormones and slowed metabolism. This is not your fault. To achieve lasting weight loss, you likely need medical or surgical interventions that override these biological defenses, as lifestyle changes alone will eventually trigger a rebound effect.

Lower drug prices for semaglutide and tirzepatide could significantly improve their cost-effectiveness, potentially making them competitive with surgical and behavioral interventions.

If drug prices for semaglutide and tirzepatide were reduced, these medications could become cost-effective options for managing class III obesity, potentially offering a non-surgical alternative.

Targeting enteroendocrine L-cells to stimulate endogenous release of GLP-1 and PYY is a viable therapeutic strategy for treating type 2 diabetes and obesity, leveraging the gut's spare hormonal capacity.

Current GLP-1 injections are effective, but research suggests that stimulating your gut's own hormone-producing cells (L-cells) using specific nutrients or future drugs could achieve similar benefits without injections. This involves targeting receptors for fats, amino acids, and bile acids in the intestine to boost natural GLP-1 and PYY release.

SGLT-2 inhibitors reduce cardiovascular and renal risks in type 2 diabetes patients by promoting glucose and sodium excretion, which triggers fatty acid beta-oxidation and depletes ectopic/visceral fat.

If you have Type 2 Diabetes and heart or kidney risks, ask your doctor about SGLT-2 inhibitors. These medications not only lower blood sugar but also help reduce harmful fat around your organs, which protects your heart and kidneys.

Energy-restricted diets have limited efficacy in reducing body fat and preventing cardiovascular events in T2DM compared to metabolic surgery or newer pharmacological interventions.

While healthy eating is crucial for T2DM, energy-restricted diets alone may not significantly reduce body fat or prevent heart problems in the long term. Combining diet with newer medications that target fat loss may be more effective.

Obesity severity (Class I, II, III) is directly correlated with increased direct medical costs, with Class III obesity costing up to 3.3 times more than normal weight individuals.

Higher obesity classes (II and III) are associated with significantly higher medical costs (up to 3.3x normal weight). This highlights the economic urgency of addressing obesity, especially in higher severity classes, through early intervention.

Intracerebroventricular administration of the GLP-1 receptor agonist Exendin-4(1-32)K-capric acid (Ex-4c) suppresses food intake and body weight gain in mice by directly activating arcuate pro-opiomelanocortin (POMC) neurons.

This research identifies that a specific GLP-1 agonist (Ex-4c) reduces food intake by directly activating POMC neurons in the hypothalamus. The mechanism involves the closure of KATP channels via PKA-dependent signaling. While this is preclinical data in mice, it supports the broader class of GLP-1 agonists used for obesity treatment by confirming a central neural mechanism involving appetite suppression.

Commercially available protein powders in the Hungarian market do not contain significant heavy metal contamination (lead, mercury, cadmium, arsenic) above regulatory safety limits.

If you buy protein powder from a reputable retailer in a regulated market (like the EU or USA), you do not need to worry about dangerous levels of heavy metals like lead or mercury. The products tested in this study were safe. However, because regulation is often voluntary, buying from unknown sources or unregulated 'grey markets' carries a higher risk of contamination.

Spinach thylakoid supplementation does not significantly improve renal function markers (urea, creatinine, total protein) in obese PCOS women compared to placebo, despite improvements in other metabolic indices.

Do not take spinach thylakoid extract expecting it to improve kidney function. While it helps with metabolic markers, this study showed no benefit for renal markers like urea or creatinine in obese PCOS women.

Post-bariatric surgery patients, particularly those undergoing Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion (BPD), are at high risk for postprandial hyperinsulinemic hypoglycemia (PHG) due to accelerated carbohydrate delivery to the small intestine, which triggers excessive GLP-1 secretion and subsequent insulin hypersecretion.

If you have had gastric bypass surgery, be aware that eating simple sugars can cause a dangerous drop in blood sugar 2-3 hours later. This is caused by your body overproducing insulin in response to fast-absorbing carbs. Manage this by strictly limiting simple sugars and focusing on complex carbohydrates and fiber to slow absorption.

Insulin-sensitizing agents (DPP4 inhibitors, SGLT2 inhibitors, GLP-1 analogues) reduce atherosclerosis risk by modulating perivascular adipose tissue (PVAT) biology, specifically by reducing inflammatory adipokines like ceramides and restoring vascular insulin sensitivity.

If you have obesity and heart risk, medications like GLP-1 analogues (e.g., liraglutide) can help your heart vessels directly, not just by helping you lose weight. They reduce harmful fats (ceramides) in your blood that cause inflammation around your arteries. This happens even if your weight doesn't change much, showing that these drugs protect your heart independently of weight loss.

High host-driven digestibility (HDD) diets, such as ultra-processed foods, decouple host and microbial nutrient status by maximizing small intestinal absorption, which leads to host energy surplus and gut microbial nutrient limitation.

To optimize gut health and metabolic balance, prioritize foods with low host-driven digestibility (high fiber, resistant starch, whole foods). These foods escape small intestinal absorption, reaching the colon to feed beneficial microbes, which in turn produce short-chain fatty acids that support host health. Ultra-processed, high-digestibility foods absorb quickly, leading to host energy surplus and starving the gut microbiome.

High intake of saturated fatty acids (SFA) at the population level is not associated with increased cardiovascular disease (CVD) incidence or mortality, provided the SFA is not replaced by low-quality carbohydrates.

You do not need to fear saturated fats if your overall diet is balanced. The key is not to replace fats with refined sugars or white flour. Focus on whole foods, adequate protein, and healthy fats rather than strictly limiting total fat grams.